Human pancreatic islets produce GLP-2 locally and express its receptor; activating this receptor reduced inflammation by dampening macrophage activation, though it didn't directly affect insulin secretion.
Anti-inflammatory but not insulin-alteringGLP-2R activation specifically reduced macrophage-driven inflammation in islets while having zero effect on insulin secretion — a purely protective, not metabolic, role
What the researchers found
Human islets actively secrete GLP-2 under normal conditions, and this secretion increases under diabetic stress conditions (high glucose/palmitate, inflammatory cytokines, and LPS). The DPP-4 inhibitor linagliptin markedly potentiated GLP-2 levels by preventing its breakdown.
GLP-2 receptor (GLP-2R) mRNA was found in islets from all 10 donors tested, though expression was low and decreased under inflammatory conditions. Activating the GLP-2R with teduglutide had no effect on insulin secretion or beta cell function, but it specifically dampened macrophage-dependent inflammatory markers (IL1B and IL10) while leaving macrophage-independent cytokines (IL6, IL8, TNF) unaffected. The GLP-2R antagonist GLP-2(3-33) reversed this anti-inflammatory effect, confirming it was receptor-mediated. Conditioned media from teduglutide-treated islets also reduced M1-like (pro-inflammatory) polarization of macrophages, including lower production of itaconate and succinate — metabolic markers of activated inflammatory macrophages.
Why it matters
Chronic low-grade inflammation is increasingly recognized as a central driver of beta cell failure in type 2 diabetes. This study reveals that the pancreas has its own local GLP-2 system that may serve as a built-in anti-inflammatory defense for islets. The finding also has implications for DPP-4 inhibitor therapy — these drugs (like linagliptin) prevent the breakdown of both GLP-1 and GLP-2, meaning their pancreatic benefits may partly come from enhanced local GLP-2 signaling, not just GLP-1. This opens a new dimension of understanding how incretin-based diabetes drugs actually work.
The numbers in context
10 donors; GLP-2 secretion increased by stress; linagliptin potentiated; teduglutide reduced IL1B/IL10; reduced M1 polarization; no insulin secretion effect
How the study worked
Isolated human islets from 10 non-diabetic donors exposed to diabetogenic conditions (high glucose, palmitate, cytokines, LPS) with/without linagliptin, teduglutide, and GLP-2(3-33) antagonist. GLP-2 secretion, GLP-2R expression, insulin secretion, cytokine expression, and macrophage polarization measured.
Who was studied
Isolated human islets from 10 non-diabetic donors
What this study cannot tell us
This is an in vitro study using isolated human islets — not a study in living patients. Only 10 donors were used, and GLP-2R expression was low, raising questions about how physiologically significant the receptor signaling is. The anti-inflammatory effect operated through an indirect mechanism (islet-macrophage crosstalk), making it more complex and harder to predict in vivo. No animal models or clinical data were included. The study doesn't determine whether GLP-2's anti-inflammatory effect actually protects beta cells from destruction over time.
How to read the evidence
Rated moderate because the study uses human tissue (not animal), includes islets from 10 donors for reproducibility, employs both agonist and antagonist to confirm receptor specificity, and includes metabolic profiling of macrophage polarization. However, it remains an in vitro study with no in vivo validation.
When this study was published
Published in 2021, this study reflects growing scientific interest in the non-gut roles of GLP-2 and the inflammatory mechanisms underlying type 2 diabetes. The findings remain highly relevant as researchers continue to explore multi-target incretin-based approaches to diabetes treatment.
The bigger picture
GLP-1 and GLP-2 are both derived from proglucagon, but while GLP-1 has become one of the biggest drug stories in modern medicine, GLP-2 has been studied almost exclusively for its gut effects (teduglutide is approved for short bowel syndrome). This study suggests GLP-2 has an entirely separate role inside the pancreas — acting as a local anti-inflammatory mediator through immune cell crosstalk. This fits a broader emerging paradigm where incretin peptides are recognized as having multi-organ effects far beyond their originally described functions.
Questions still open
- Could adding GLP-2R activation to existing GLP-1-based diabetes therapy provide additional beta cell protection through reduced islet inflammation?
- How much of the clinical benefit of DPP-4 inhibitors is actually mediated through local GLP-2 preservation in the pancreas versus GLP-1?
- Does the local GLP-2 anti-inflammatory system fail in type 2 diabetes, potentially contributing to beta cell loss?
Common questions
What's the difference between GLP-1 and GLP-2?
Why does islet inflammation matter for diabetes?
Read the original research
GLP-2 Is Locally Produced From Human Islets and Balances Inflammation Through an Inter-Islet-Immune Cell Crosstalk.
Frontiers in endocrinology, 12, 697120
Citation
He, Wei; Rebello, Osmond D; Henne, Antonia; Nikolka, Fabian; Klein, Thomas; Maedler, Kathrin. (2021). GLP-2 Is Locally Produced From Human Islets and Balances Inflammation Through an Inter-Islet-Immune Cell Crosstalk.. Frontiers in endocrinology, 12, 697120. https://doi.org/10.3389/fendo.2021.697120